Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110038 | 0.89 | HTR3A (0.46) | HTR3A | |
| SCHEMBL5113328 | 0.83 | HTR3A (0.41) | HTR3A | |
| SCHEMBL4985415 | 0.78 | HTR3A (0.48) | HTR3ACHRNB2CHRNA4 | |
| SCHEMBL4985407 | 0.78 | HTR3A (0.48) | HTR3ACHRNB2CHRNA4 | |
| SCHEMBL13733192 | 0.77 | HTR3A (0.71) | HTR3ACHRNB2CHRNA4 | |
| SCHEMBL15441263 | 0.77 | HTR3A (0.71) | HTR3ACHRNB2CHRNA4 | |
| SCHEMBL5110768 | 0.68 | KCNH2 (0.57) | — | |
| SCHEMBL4986626 | 0.68 | DRD2 (0.50) | CHRNB2CHRNA4 | |
| SCHEMBL4986638 | 0.68 | DRD2 (0.50) | CHRNB2CHRNA4 | |
| SCHEMBL9024333 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | claimed |
| EP-1831212-A1 | NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | claimed |
| WO-2006065217-A1 | NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNG, CHRNE, CHRNA1 | HTR3A 214/4885CHRNB2 16/4885CHRNA4 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.